#USA #New York #Class Action #Pomerantz LLP #uniQure N.V.

Pomerantz Law Firm Launches Class Action Against uniQure N.V.

On February 26, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against uniQure N.V. (NASDAQ: QURE). This legal proceeding centers around allegations of misconduct by the company and various executive members, suggesting potential securities fraud and other unlawful business practices. Investors who have faced losses are encouraged to take action by contacting the firm to possibly join the lawsuit.

Important Deadlines for Investors

Affected investors must act swiftly, as the deadline to apply for Lead Plaintiff status in the class action is April 13, 2026. This status allows investors to represent the class and advocate for their collective interests in court. Interested parties should reach out to Danielle Peyton at Pomerantz LLP for more information and should prepare to provide relevant details such as their mailing address, phone number, and the number of shares they acquired.

Background of the Case

The class action arises from a significant announcement made by uniQure on November 3, 2025. During a pre-Biologics License Application (BLA) meeting, the U.S. Food and Drug Administration (FDA) expressed reservations regarding uniQure’s proposed gene therapy for Huntington's disease, AMT-130. The company indicated that the FDA’s stance had shifted, raising concerns about the sufficiency of previous trial data as evidence for their application submission. Following this news, uniQure's stock plummeted by over 49%, underscoring the potential impact of the FDA's feedback on investor confidence.

Class Action Details

In light of these developments, the lawsuit will assess whether uniQure's management adequately communicated critical information that may have influenced their stock’s valuation. If it is determined that the company concealed important data regarding the FDA's concerns, investors could recover significant damages. Pomerantz LLP, a renowned law firm with extensive experience in corporate and securities litigation, is spearheading this lawsuit. They have a track record of securing multi-million-dollar settlements for investors in similar situations.

How to Join the Class Action

Investors wishing to join the class action against uniQure should act quickly to get in touch with Pomerantz LLP. They can submit inquiries via email or telephone, and it is beneficial to include personal contact details to expedite the process. A copy of the official complaint is accessible through the law firm’s website, providing further context on the allegations and legal rationale underpinning the lawsuit.

Conclusion

The class action lawsuit against uniQure N.V. serves as a crucial reminder for investors to stay informed about their rights and the legal avenues available for recovery in cases of potential securities fraud. As the deadline for joining the class approaches, interested investors should seize the opportunity to take part in this legal action to safeguard their investments. For more information, visit Pomerantz Law Firm or contact them directly.

Pomerantz LLP continues its legacy as a pioneer in protecting investors and holding companies accountable for their actions. Should you find yourself affected by these recent developments, remember that you are not alone; legal support is at hand to help navigate this challenging situation.